UY25436A1 - STATIN-MMP INHIBITOR COMBINATIONS - Google Patents
STATIN-MMP INHIBITOR COMBINATIONSInfo
- Publication number
- UY25436A1 UY25436A1 UY25436A UY25436A UY25436A1 UY 25436 A1 UY25436 A1 UY 25436A1 UY 25436 A UY25436 A UY 25436A UY 25436 A UY25436 A UY 25436A UY 25436 A1 UY25436 A1 UY 25436A1
- Authority
- UY
- Uruguay
- Prior art keywords
- mmp inhibitor
- statin
- inhibitor combinations
- combination
- ldl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a una combinación de un compuesto de estatina,que se sabe que causa una reducción en los niveles plasmáticos de colesterol lipoproteínas de baja densidad (ldl),y un inhibidor de mmp,que reduce la ruptura de tejidos conectivos. La combinación es útil para tratar trastornos vasculares y prevenir la insuficiencia cardiaca.The invention relates to a combination of a statin compound, known to cause a reduction in plasma levels of low-density lipoprotein cholesterol (LDL), and an mmp inhibitor, which reduces the breakdown of connective tissues. The combination is useful for treating vascular disorders and preventing heart failure.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7826598P | 1998-03-17 | 1998-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25436A1 true UY25436A1 (en) | 2001-10-25 |
Family
ID=22142950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25436A UY25436A1 (en) | 1998-03-17 | 1999-03-16 | STATIN-MMP INHIBITOR COMBINATIONS |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1063991A1 (en) |
| JP (1) | JP2002506818A (en) |
| KR (1) | KR20010041916A (en) |
| AR (1) | AR018113A1 (en) |
| AU (1) | AU1591699A (en) |
| BR (1) | BR9815745A (en) |
| CA (1) | CA2309588A1 (en) |
| CO (1) | CO5070670A1 (en) |
| GT (1) | GT199900039A (en) |
| HN (1) | HN1999000029A (en) |
| MY (1) | MY140504A (en) |
| NZ (1) | NZ505994A (en) |
| PA (1) | PA8469001A1 (en) |
| PE (1) | PE20000348A1 (en) |
| SV (1) | SV1999000026A (en) |
| UY (1) | UY25436A1 (en) |
| WO (1) | WO1999047138A1 (en) |
| ZA (1) | ZA992106B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| CA2590278A1 (en) | 2004-12-15 | 2006-06-22 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US20110182851A1 (en) * | 2008-07-11 | 2011-07-28 | Jan Nilsson | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE348607T1 (en) * | 1995-11-02 | 2007-01-15 | Warner Lambert Co | METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION |
| JP2000511175A (en) * | 1996-05-17 | 2000-08-29 | ワーナー―ランバート・コンパニー | Biphenylsulfonamide matrix metalloproteinase inhibitor |
| NZ334897A (en) * | 1996-12-09 | 2001-02-23 | Warner Lambert Co | Medicaments for treating and preventing heart failure and ventricular dilatation |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GT199800126A (en) * | 1997-08-29 | 2000-01-29 | COMBINATION THERAPY. |
-
1998
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Application Discontinuation
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/en active Pending
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/en not_active Application Discontinuation
- 1998-11-20 NZ NZ505994A patent/NZ505994A/en unknown
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/en not_active Application Discontinuation
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/en unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/en unknown
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/en unknown
- 1999-03-16 GT GT199900039A patent/GT199900039A/en unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/en not_active Application Discontinuation
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/en unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/en not_active Application Discontinuation
- 1999-03-16 UY UY25436A patent/UY25436A1/en not_active Application Discontinuation
- 1999-03-16 CO CO99016109A patent/CO5070670A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT199900039A (en) | 2000-09-06 |
| HN1999000029A (en) | 1999-09-29 |
| AU1591699A (en) | 1999-10-11 |
| CA2309588A1 (en) | 1999-09-23 |
| MY140504A (en) | 2009-12-31 |
| NZ505994A (en) | 2003-10-31 |
| CO5070670A1 (en) | 2001-08-28 |
| ZA992106B (en) | 1999-09-30 |
| WO1999047138A1 (en) | 1999-09-23 |
| SV1999000026A (en) | 2000-01-18 |
| JP2002506818A (en) | 2002-03-05 |
| BR9815745A (en) | 2000-11-14 |
| PE20000348A1 (en) | 2000-05-22 |
| EP1063991A1 (en) | 2001-01-03 |
| KR20010041916A (en) | 2001-05-25 |
| AR018113A1 (en) | 2001-10-31 |
| PA8469001A1 (en) | 2002-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP074704A (en) | INHIBITOR COMBINATIONS (S) OF STEROL ABSORPTION WITH BLOOD MODIFIER (S) TO TREAT VASCULAR TABLES | |
| UY25268A1 (en) | INHIBITION OF LIPOPROTEIN OXIDATION | |
| DK0840732T3 (en) | Substituted benzolactam compounds as substance P antagonists | |
| EA200100707A1 (en) | COMBINATIONS OF INHIBITORS OF TRANSPORT OF BILK ACIDS IN THE SUBJECTIVE AND FIBRIN ACID DERIVATIVES FOR THE CARDIOVASCULAR INDICATIONS | |
| CY1107174T1 (en) | ASPIRINE RELIEF COMBINATIONS FOR VASCULAR THERAPY | |
| EA199800667A1 (en) | NEW PHENANTRIDINES | |
| CY1106915T1 (en) | Bile acid separator and sterol absorption inhibitors and vasoconstrictor therapies | |
| UY25322A1 (en) | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS TO TREAT AND PREVENT INFLAMMATORY DISEASES AND ATEROSCLEROSIS | |
| UY25299A1 (en) | STATIN-CARBOXYALKYL ETHER COMBINATIONS | |
| DK0971713T3 (en) | Use of cholinesterase inhibitors to treat attention disorders | |
| BR9911440A (en) | Composition for the prevention and / or treatment of osteoporosis and changes due to menopause syndrome | |
| CO4970724A1 (en) | COMBINATION THERAPY | |
| BR0212252A (en) | Methods to Reduce Hypertension and Heart Failure in a Mammal | |
| HK1064950A1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
| EA200300953A1 (en) | THERAPEUTIC COMBINATIONS FOR USE IN CARDIOVASCULAR AND INFLAMMATORY DISEASES | |
| IL110943A0 (en) | Compositions for the treatment of skin disorders | |
| EE200100155A (en) | A method of treating atherosclerosis using an a2 inhibitor and a combination thereof | |
| ES2184111T3 (en) | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES CONTAINING ANTIDEPRESSANTS AND / OR INHIBITORS OF MONOAMINOXIDASE AND / OR VITAMIN B12 AND / OR PRECURSORS OR INDUCERS OF A NEUROTRANSMITTER. | |
| CL2004000366A1 (en) | USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION. | |
| PT1032414E (en) | COMBINATION OF AN INHIBITOR OF THE ANGIOTENSIN CONVERSATION ENZYME AND A DIURETIC FOR THE TREATMENT OF MICROCIRCULATORY DISTURBACTIONS | |
| WO2005046797A3 (en) | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions | |
| NZ503962A (en) | ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis | |
| UY25436A1 (en) | STATIN-MMP INHIBITOR COMBINATIONS | |
| BR9713522A (en) | Method of using cyclooxygenase-2 inhibitors as antiangiogenic agents. | |
| EA199901043A1 (en) | PHARMACEUTICAL TRANSFERASE INHIBITORS IN A COMBINATION WITH HMG-CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20110104 |